Highlights and Quick Summary
- EBIT Margin for the quarter ending March 31, 2022 was -44.87% (a -32.73% decrease compared to previous quarter)
- Year-over-year quarterly EBIT Margin increased by 103.49%
- Annual EBIT Margin for 2021 was -40.9% (a -96.73% decrease from previous year)
- Annual EBIT Margin for 2020 was -1251.71% (a 122.09% increase from previous year)
- Annual EBIT Margin for 2019 was -563.61% (a 584.66% increase from previous year)
- Twelve month EBIT Margin ending March 31, 2022 was -53.46% (a 30.71% increase compared to previous quarter)
- Twelve month trailing EBIT Margin decreased by -80.16% year-over-year
Trailing EBIT Margin for the last four month:
| 31 Mar '22 | 31 Dec '21 | 30 Sep '21 | 30 Jun '21 |
|---|---|---|---|
| -53.46% | -40.9% | -203.37% | -269.39% |
Visit stockrow.com/ORGS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBIT Margin of Orgenesis Inc.
Most recent EBIT Marginof ORGS including historical data for past 10 years.Interactive Chart of EBIT Margin of Orgenesis Inc.
Orgenesis Inc. EBIT Margin for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year | |
|---|---|---|---|---|---|---|
| 2022 | -44.87% | – | – | – | – | |
| 2021 | -66.7% | -88.24% | -22.05% | 0.6% | -40.9% | |
| 2020 | -2305.23% | -540.54% | -1530.82% | -358.52% | -1251.71% | |
| 2019 | -453.27% | -307.06% | -428.38% | -1977.09% | -563.61% | |
| 2018 | -133.72% | -10.35% | -69.33% | -122.84% | -82.32% | |
| 2017 | -133.18% | -101.13% | 0.0% | -186.07% | -198.55% | |
| 2016 | 0.0% | -132.07% | 0.0% | -350.97% | -308.04% | 0.0% |
| 2015 | – | – | – | – | -242.47% | |
| 2014 | – | – | – | – | 0.0% | |
| 2013 | – | – | – | – | 0.0% | |
| 2012 | – | – | – | – | 0.0% | |
| 2011 | – | – | – | – | 0.0% |
Business Profile of Orgenesis Inc.
Sector: Healthcare
Industry: Biotechnology